Summit Therapeutics shared a post on LinkedIn:
“Are you attending WCLC 2025? Then please MARK YOUR CALENDARS to view –ivonescimab Akeso poster: P1.11.83. Ivonescimab vs. Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONi-2 by Tumor Histology Presenter: Dr Anwen Xiong, Date/Time: Sunday, September 7, 2025, 10:30 – 12:00pm CEST, Location – Exhibit Hall
Important Summit WCLC 2025 Quick Facts – This link has what you need to know.
We look forward to seeing you in Barcelona Spain at Summit’s Medical Affairs Booth 204!
*Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
More posts featuring Summit Therapeutics on OncoDaily.